Bristol-Myers Squibb Company Company Profile (NYSE:BMY)

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company logoBristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience; cardiovascular, and neuroscience. Its late-stage investigational compounds that are in Phase III clinical trials include Beclabuvir, BMS-663068 and Prostvac.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: Pharmaceuticals
  • Exchange: NYSE
  • Symbol: BMY
  • CUSIP: 11012210
Key Metrics:
  • Previous Close: $55.77
  • 50 Day Moving Average: $53.27
  • 200 Day Moving Average: $55.17
  • 52-Week Range: $46.01 - $77.12
  • Trailing P/E Ratio: 21.05
  • Foreward P/E Ratio: 18.05
  • P/E Growth: 1.36
  • Market Cap: $93.20B
  • Outstanding Shares: 1,671,229,000
  • Beta: 1
  • Net Margins: 22.94%
  • Return on Equity: 31.39%
  • Return on Assets: 14.48%
  • Debt-to-Equity Ratio: 0.37%
  • Current Ratio: 1.47%
  • Quick Ratio: 1.30%
Additional Links:
Companies Related to Bristol-Myers Squibb Company:

Analyst Ratings

Consensus Ratings for Bristol-Myers Squibb Company (NYSE:BMY) (?)
Ratings Breakdown: 1 Sell Rating, 11 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.35)
Consensus Price Target: $61.83 (10.87% upside)

Analysts' Ratings History for Bristol-Myers Squibb Company (NYSE:BMY)
DateFirmActionRatingPrice TargetDetails
2/22/2017ArgusReiterated RatingBuy$75.00View Rating Details
2/21/2017BMO Capital MarketsReiterated RatingMarket Perform$45.00View Rating Details
2/16/2017Deutsche Bank AGReiterated RatingHold$42.00View Rating Details
2/9/2017GabelliReiterated RatingBuyView Rating Details
1/31/2017Jefferies Group LLCReiterated RatingBuy$69.00 -> $66.00View Rating Details
1/30/2017Leerink SwannReiterated RatingOutperform$62.00View Rating Details
1/24/2017Barclays PLCLower Price TargetEqual Weight$65.00 -> $58.00View Rating Details
1/21/2017J P Morgan Chase & CoReiterated RatingBuyView Rating Details
1/20/2017Cowen and CompanyDowngradeOutperform -> Market Perform$77.12 -> $65.00View Rating Details
1/20/2017William BlairReiterated RatingOurperformView Rating Details
1/8/2017Evercore ISIReiterated RatingHold$55.00View Rating Details
11/8/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
10/28/2016Hilliard LyonsUpgradeNeutral -> Buy$69.00View Rating Details
10/17/2016Credit Suisse GroupReiterated RatingHold$58.00View Rating Details
10/13/2016Goldman Sachs Group, Inc. (The)DowngradeStrong-Buy -> Buy$75.00View Rating Details
10/10/2016SunTrust Banks, Inc.Reiterated RatingHold$68.00 -> $62.00View Rating Details
8/25/2016Morgan StanleyReiterated RatingNeutral -> HoldView Rating Details
8/11/2016Berenberg BankDowngradeBuy -> Hold$80.00 -> $70.00View Rating Details
8/11/2016Sanford C. BernsteinReiterated RatingMarket Perform$79.00 -> $65.00View Rating Details
8/8/2016Piper Jaffray CompaniesReiterated RatingNeutral$69.00 -> $65.00View Rating Details
4/6/2016Societe GeneraleInitiated CoverageSell$48.00View Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageUnderweight$57.00View Rating Details
12/2/2015GuggenheimUpgradeNeutral -> Buy$82.00View Rating Details
(Data available from 2/24/2015 forward)


Earnings History for Bristol-Myers Squibb Company (NYSE:BMY)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/26/2017Q416$0.67$0.63$5.14 billion$5.24 billionViewN/AView Earnings Details
10/27/2016Q316$0.65$0.77$4.76 billion$4.83 billionViewListenView Earnings Details
7/28/2016Q216$0.66$0.69$4.60 billion$4.90 billionViewListenView Earnings Details
4/28/2016Q116$0.65$0.74$4.19 billion$4.39 billionViewListenView Earnings Details
1/28/2016Q415$0.28$0.38$4.07 billion$4.29 billionViewListenView Earnings Details
10/27/2015Q315$0.35$0.39$3.83 billion$4.07 billionViewListenView Earnings Details
7/23/2015Q215$0.36$0.53$3.68 billion$4.16 billionViewListenView Earnings Details
4/28/2015Q115$0.50$0.71$3.80 billion$4.04 billionViewN/AView Earnings Details
1/27/2015Q414$0.41$0.46$4.02 billion$4.26 billionViewN/AView Earnings Details
10/24/2014Q314$0.42$0.45$3.80 billion$3.92 billionViewListenView Earnings Details
7/24/2014Q214$0.44$0.48$3.85 billion$3.89 billionViewListenView Earnings Details
4/29/2014Q114$0.43$0.46$3.89 billion$3.81 billionViewListenView Earnings Details
1/24/2014Q413$0.43$0.53$4.30 billion$4.44 billionViewListenView Earnings Details
10/23/2013Q313$0.44$0.46$4.02 billion$4.07 billionViewListenView Earnings Details
7/25/2013Q2 2013$0.45$0.44$4.07 billion$4.05 billionViewListenView Earnings Details
4/25/2013Q1 2013$0.41$0.41$3.88 billion$3.83 billionViewListenView Earnings Details
1/24/2013Q4 2012$0.42$0.47$4.14 billion$4.19 billionViewListenView Earnings Details
10/24/2012$0.42$0.41ViewN/AView Earnings Details
7/25/2012$0.48$0.48ViewN/AView Earnings Details
4/26/2012$0.64$0.64ViewN/AView Earnings Details
1/26/2012$0.55$0.53ViewN/AView Earnings Details
10/27/2011$0.58$0.61ViewN/AView Earnings Details
7/28/2011$0.55$0.56ViewN/AView Earnings Details
4/28/2011$0.53$0.58ViewN/AView Earnings Details
1/27/2011$0.48$0.47ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Bristol-Myers Squibb Company (NYSE:BMY)
Current Year EPS Consensus Estimate: $2.81 EPS
Next Year EPS Consensus Estimate: $3.09 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164$0.63$0.66$0.64
Q2 20164$0.65$0.69$0.67
Q3 20164$0.61$0.66$0.64
Q4 20164$0.52$0.68$0.59
Q1 20172$0.69$0.71$0.70
Q2 20172$0.66$0.69$0.68
Q3 20172$0.66$0.76$0.71
Q4 20172$0.63$0.76$0.70
Q1 20181$0.70$0.70$0.70
Q2 20181$0.72$0.72$0.72
Q3 20181$0.77$0.77$0.77
Q4 20181$0.81$0.81$0.81
(Data provided by Zacks Investment Research)


Current Dividend Information for Bristol-Myers Squibb Company (NYSE:BMY)
Annual Dividend:$1.56
Dividend Yield:2.80%
Dividend Growth:2.80% (3 Year Average)
Payout Ratio:58.87% (Based on Trailing 12 Months of Earnings)
55.52% (Based on Current Year Consensus EPS Estimate)
50.49% (Based on Next Year Consensus EPS Estimate)
Track Record:7 Years of Consecutive Dividend Growth

Dividend History for Bristol-Myers Squibb Company (NYSE:BMY)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for Bristol-Myers Squibb Company (NYSE:BMY)
Insider Ownership Percentage: 0.24%
Institutional Ownership Percentage: 69.67%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/8/2016Lamberto AndreottiDirectorSell21,600$56.87$1,228,392.00View SEC Filing  
8/25/2016Lamberto AndreottiDirectorSell23,200$59.17$1,372,744.00View SEC Filing  
7/8/2016Lamberto AndreottiDirectorSell23,200$74.45$1,727,240.00View SEC Filing  
6/28/2016Lamberto AndreottiDirectorSell23,200$72.14$1,673,648.00View SEC Filing  
6/14/2016John E ElickerSVPSell11,820$72.69$859,195.80View SEC Filing  
5/20/2016Charles A BancroftCFOSell30,201$70.79$2,137,928.79View SEC Filing  
5/16/2016Joseph C CaldarellaSVPSell3,519$72.47$255,021.93View SEC Filing  
5/6/2016Sandra LeungEVPSell72,544$70.39$5,106,372.16View SEC Filing  
5/5/2016Lamberto AndreottiDirectorSell23,200$70.54$1,636,528.00View SEC Filing  
5/3/2016Giovanni CaforioCEOSell34,594$71.31$2,466,898.14View SEC Filing  
5/2/2016Autenried Paul VonSVPSell37,258$71.93$2,679,967.94View SEC Filing  
5/2/2016Lamberto AndreottiDirectorSell234,720$71.88$16,871,673.60View SEC Filing  
5/2/2016Louis S SchmuklerInsiderSell22,218$71.95$1,598,585.10View SEC Filing  
4/5/2016Lamberto AndreottiDirectorSell23,200$65.90$1,528,880.00View SEC Filing  
4/4/2016Lamberto AndreottiDirectorSell11,600$65.79$763,164.00View SEC Filing  
3/9/2016Lamberto AndreottiDirectorSell23,200$65.71$1,524,472.00View SEC Filing  
3/8/2016Lewis B CampbellDirectorSell2,500$66.00$165,000.00View SEC Filing  
3/4/2016Joseph C CaldarellaSVPSell12,962$64.64$837,863.68View SEC Filing  
2/17/2016Giovanni CaforioCEOSell12,040$63.58$765,503.20View SEC Filing  
2/17/2016Sandra LeungEVPSell10,152$63.57$645,362.64View SEC Filing  
2/12/2016Lamberto AndreottiDirectorSell23,200$59.61$1,382,952.00View SEC Filing  
1/5/2016Lamberto AndreottiDirectorSell23,200$67.56$1,567,392.00View SEC Filing  
1/4/2016Lamberto AndreottiDirectorSell11,600$66.93$776,388.00View SEC Filing  
12/15/2015Lamberto AndreottiDirectorSell23,200$69.03$1,601,496.00View SEC Filing  
11/20/2015Lamberto AndreottiDirectorSell23,200$67.39$1,563,448.00View SEC Filing  
10/6/2015Lamberto AndreottiDirectorSell23,200$60.86$1,411,952.00View SEC Filing  
9/3/2015Lamberto AndreottiDirectorSell23,200$59.40$1,378,080.00View SEC Filing  
6/4/2015Joseph C CaldarellaSVPSell16,972$65.71$1,115,230.12View SEC Filing  
3/16/2015Francis M CussEVPSell114,666$67.81$7,775,501.46View SEC Filing  
3/16/2015Louis S SchmuklerInsiderSell12,000$66.96$803,520.00View SEC Filing  
2/17/2015Sandra LeungGeneral CounselSell11,746$60.39$709,340.94View SEC Filing  
2/12/2015Samuel J MoedSVPSell3,880$59.26$229,928.80View SEC Filing  
2/6/2015Samuel J MoedSVPSell21,478$60.15$1,291,901.70View SEC Filing  
1/29/2015Lamberto AndreottiCEOSell90,246$61.14$5,517,640.44View SEC Filing  
1/29/2015Lewis B CampbellDirectorSell2,500$60.89$152,225.00View SEC Filing  
1/29/2015Louis S SchmuklerInsiderSell5,250$60.73$318,832.50View SEC Filing  
12/5/2014Lamberto AndreottiCEOSell75,000$60.31$4,523,250.00View SEC Filing  
10/24/2014Lamberto AndreottiCEOSell50,000$53.00$2,650,000.00View SEC Filing  
10/6/2014Lamberto AndreottiCEOSell50,000$50.99$2,549,500.00View SEC Filing  
9/16/2014Francis M CussEVPSell63,667$50.77$3,232,373.59View SEC Filing  
9/15/2014Giovanni CaforioCOOSell26,691$49.87$1,331,080.17View SEC Filing  
9/10/2014Joseph C CaldarellaSVPSell7,415$51.03$378,387.45View SEC Filing  
9/8/2014Lamberto AndreottiCEOSell50,000$51.05$2,552,500.00View SEC Filing  
8/19/2014Autenried Paul VonSVPSell20,000$49.89$997,800.00View SEC Filing  
7/29/2014Charles A BancroftCFOSell67,621$51.06$3,452,728.26View SEC Filing  
7/28/2014Samuel J MoedSVPSell25,752$49.32$1,270,088.64View SEC Filing  
3/13/2014Joseph CaldarellaSVPSell9,137$55.20$504,362.40View SEC Filing  
3/10/2014Lamberto AndreottiCEOSell100,000$55.52$5,552,000.00View SEC Filing  
3/10/2014Louis SchmuklerInsiderSell8,799$55.81$491,072.19View SEC Filing  
3/5/2014James CorneliusDirectorSell100,000$55.82$5,582,000.00View SEC Filing  
2/28/2014Louis SchmuklerInsiderSell6,088$54.49$331,735.12View SEC Filing  
2/24/2014Giovanni CaforioEVPSell41,563$54.44$2,262,689.72View SEC Filing  
2/19/2014John ElickerSVPSell9,534$54.22$516,933.48View SEC Filing  
2/18/2014Francis CussEVPSell29,800$54.61$1,627,378.00View SEC Filing  
2/14/2014Charles BancroftCFOSell52,963$54.35$2,878,539.05View SEC Filing  
2/14/2014Sandra LeungGeneral CounselSell10,490$54.28$569,397.20View SEC Filing  
2/11/2014Lamberto AndreottiCEOSell86,075$52.66$4,532,709.50View SEC Filing  
2/6/2014Joseph CaldarellaSVPSell35,471$48.90$1,734,531.90View SEC Filing  
2/5/2014Lewis CampbellDirectorSell2,500$48.28$120,700.00View SEC Filing  
2/4/2014James CorneliusDirectorSell100,000$48.90$4,890,000.00View SEC Filing  
7/29/2013James M CorneliusDirectorSell5,000$43.81$219,050.00View SEC Filing  
6/10/2013Autenried Paul VonSVPSell25,000$47.24$1,181,000.00View SEC Filing  
6/6/2013Joseph C CaldarellaSVPSell26,275$46.53$1,222,575.75View SEC Filing  
6/5/2013John E ElickerSVPSell25,997$46.33$1,204,441.01View SEC Filing  
6/4/2013Lamberto AndreottiCEOSell100,000$47.74$4,774,000.00View SEC Filing  
6/4/2013Samuel J MoedSVPSell58,898$47.38$2,790,587.24View SEC Filing  
6/3/2013Elliot SigalEVPSell83,647$48.18$4,030,112.46View SEC Filing  
5/31/2013Beatrice J CazalaEVPSell91,282$47.00$4,290,254.00View SEC Filing  
5/31/2013Giovanni CaforioInsiderSell10,538$47.06$495,918.28View SEC Filing  
5/30/2013Beatrice J CazalaEVPSell22,000$47.00$1,034,000.00View SEC Filing  
5/28/2013Charles A BancroftCFOSell25,000$48.68$1,217,000.00View SEC Filing  
5/28/2013James M CorneliusDirectorSell100,000$47.61$4,761,000.00View SEC Filing  
5/23/2013Beatrice J CazalaEVPSell96,000$46.99$4,511,040.00View SEC Filing  
5/23/2013Giovanni CaforioInsiderSell26,647$46.29$1,233,489.63View SEC Filing  
5/17/2013James M CorneliusDirectorSell225,996$42.99$9,715,568.04View SEC Filing  
5/8/2013James M CorneliusDirectorSell20,000$39.85$797,000.00View SEC Filing  
5/2/2013James M CorneliusDirectorSell20,000$39.76$795,200.00View SEC Filing  
4/11/2013James M CorneliusDirectorSell20,000$41.15$823,000.00View SEC Filing  
3/13/2013James M CorneliusDirectorSell20,000$38.18$763,600.00View SEC Filing  
3/13/2013John E ElickerSVPSell3,409$38.51$131,280.59View SEC Filing  
2/27/2013Giovanni CaforioInsiderSell12,150$37.08$450,522.00View SEC Filing  
2/26/2013James M CorneliusDirectorSell20,000$36.58$731,600.00View SEC Filing  
1/17/2013James M CorneliusDirectorSell20,000$34.33$686,600.00View SEC Filing  
12/28/2012James M CorneliusDirectorSell20,000$32.06$641,200.00View SEC Filing  
10/3/2012James M CorneliusDirectorSell20,000$33.71$674,200.00View SEC Filing  
8/10/2012James M CorneliusDirectorSell10,000$31.81$318,100.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Bristol-Myers Squibb Company (NYSE:BMY)
News IconNotable Stock Analysts Ratings: Bristol-Myers Squibb Company (NYSE:BMY) (NYSE:BMY) - February 23 at 8:58 PM logoCarl Icahn’s Stake in Bristol-Myers Squibb Co (BMY) Fuels Takeover Talk (NYSE:BMY) - February 23 at 3:57 PM
News IconBristol-Myers Squibb Company (BMY) Rating Reiterated by BMO Capital Markets (NYSE:BMY) - February 23 at 3:57 PM logoAnalyst Activity – Argus Reiterates Buy on Bristol-Myers Squibb Company (NYSE:BMY) (NYSE:BMY) - February 23 at 3:57 PM
News IconForward Earnings Estimate of Bristol-Myers Squibb Company(BMY) (NYSE:BMY) - February 23 at 3:57 PM logoCompany News for February 23, 2017 (NYSE:BMY) - February 23 at 3:57 PM logoMerck, Roche Gouge Bristol's I-O Share After Lung Cancer Approvals (NYSE:BMY) - February 23 at 3:57 PM logoBristol-Myers Squibb Co (BMY) To Sell Senior Notes As Formidable Activist Investor Shows Interest (NYSE:BMY) - February 23 at 3:57 PM logoBRIEF-Bristol-Myers Squibb prices $1.5 billion of senior notes (NYSE:BMY) - February 23 at 2:08 AM logoFitch Rates Bristol-Myers Squibb's Notes Offering 'A-'; Outlook Stable (NYSE:BMY) - February 22 at 9:05 PM logoBristol-Myers Squibb Prices $1.5 Billion of Senior Notes (NYSE:BMY) - February 22 at 9:05 PM logo6:01 pm Bristol-Myers agreed to sell $1.5 billion of senior unsecured notes: $750 million in aggregate principal amount of 1.600% notes due 2019 and $750 million in aggregate principal amount of 3.250% notes due 2027, in an underwritten pub (NYSE:BMY) - February 22 at 9:05 PM logoCramer: Buyers for Bristol-Myers Are Few and Far Between (NYSE:BMY) - February 22 at 9:05 PM logoYou'd be a fool to bet against the market now: Cramer (NYSE:BMY) - February 22 at 9:05 PM logoWho Could Buy Bristol-Myers Squibb? (NYSE:BMY) - February 22 at 6:57 PM logoCarl Icahn’s Stake in Bristol-Myers Squibb Co (BMY) Fuels Takeover Talk (NYSE:BMY) - February 22 at 6:27 PM
News IconDrug Manufacturers – Major: Bristol-Myers Squibb Company (NYSE:BMY) Position of the day (NYSE:BMY) - February 22 at 4:03 PM logoTakeover speculation surrounds Bristol-Myers Squibb (NYSE:BMY) - February 22 at 4:03 PM logoUS STOCKS-S&P, Nasdaq dip ahead of Fed minutes; Dow hits record high (NYSE:BMY) - February 22 at 4:03 PM logoExelixis (EXEL) Q4 Earnings: Is Positive Surprise in Store? (NYSE:BMY) - February 22 at 4:03 PM
News IconCarl Icahn just jumped into a $90 billion drug maker, and people are betting it'll be a takeover target (NYSE:BMY) - February 22 at 1:07 PM logoAnalyst Activity – BMO Capital Markets Reiterates Market Perform on Bristol-Myers Squibb Company (NYSE:BMY) (NYSE:BMY) - February 22 at 12:00 PM
News IconCarl Icahn Takes Stake in Bristol-Myers Squibb (NYSE:BMY) - February 22 at 12:00 PM
News IconBristol-Myers Squibb Company (BMY) Shares Bought by Essex Financial Services Inc (NYSE:BMY) - February 22 at 12:00 PM logoRecent BMY News (NYSE:BMY) - February 22 at 12:00 PM
News IconBroker Changes For Bristol-Myers Squibb Company (NYSE:BMY) (NYSE:BMY) - February 22 at 12:00 PM logoIs Carl Icahn Targeting Bristol-Myers Squibb for a Takeover? (BMY) (NYSE:BMY) - February 22 at 12:00 PM logoStock Futures Waver as Wall Street Awaits Clarity From the Fed (NYSE:BMY) - February 22 at 12:00 PM logoBristol-Myers Squibb Company -- Moody's rates Bristol's notes A2; negative outlook (NYSE:BMY) - February 22 at 12:00 PM logoThis bullish stock signal has never been wrong — and it’s about to flash for 2017 (NYSE:BMY) - February 22 at 12:00 PM logoDow Turns Positive in Wishy-Washy Trading Ahead of Fed Minutes (NYSE:BMY) - February 22 at 12:00 PM logoStocks Mostly Lower in Wishy-Washy Trading Ahead of Fed Minutes (NYSE:BMY) - February 22 at 12:00 PM logoUS STOCKS-Wall St slightly lower ahead of Fed minutes (NYSE:BMY) - February 22 at 12:00 PM logoCarl Icahn's Next Target: Bristol-Myers Squibb (NYSE:BMY) - February 22 at 9:46 AM logoIcahn Takes Bristol-Myers Stake With M&A In Mind; Who Could Be The Acquirer? (NYSE:BMY) - February 21 at 5:21 PM logoBristol-Myers Buys Back Shares, Shuffles Board (NYSE:BMY) - February 21 at 3:20 PM logoBristol-Myers adds three directors in agreement with JANA Partners (NYSE:BMY) - February 21 at 3:20 PM logoBristol-Myers Adds Three New Directors (NYSE:BMY) - February 21 at 3:20 PM
News IconWhat is the Street Saying About Bristol-Myers Squibb Company (NYSE:BMY)? - Aiken Advocate (NYSE:BMY) - February 21 at 11:46 AM
News IconWhat Does The Chart For Bristol-Myers Squibb Company (BMY) Tell Us Presently? - NY Stock News (NYSE:BMY) - February 21 at 11:46 AM logoBristol-Myers Squibb (BMY) Announces $2B Accelerated Share Repurchase and Names Three New Independent ... - (NYSE:BMY) - February 21 at 11:46 AM logoFirst Comprehensive Pediatric Hematology-Oncology Initiative Launched in Africa (NYSE:BMY) - February 21 at 11:46 AM logo6:59 am Bristol-Myers appoints three new independent directors, announces $2 bln accelerated share repurchase program (NYSE:BMY) - February 21 at 11:46 AM logoBristol-Myers Squibb Appoints Three New Independent Directors (NYSE:BMY) - February 21 at 11:46 AM logoBristol-Myers announces $2 bln accelerated share buyback; adds former Bausch & Lomb CFO, others to board (NYSE:BMY) - February 21 at 11:46 AM logoBristol-Myers adds three directors in deal with Jana Partners (NYSE:BMY) - February 21 at 11:46 AM logoBRISTOL MYERS SQUIBB CO Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Statem (NYSE:BMY) - February 21 at 11:46 AM logoBristol-Myers adds 3 directors in agreement with JANA Partners (NYSE:BMY) - February 21 at 11:46 AM logoBristol-Myers Squibb Co (BMY), Merck & Co., Inc. (MRK), And Other Pharmaceutical Firms All Targeting I-O Segment (NYSE:BMY) - February 21 at 11:46 AM
News IconBristol-Myers Squibb Company (BMY) : Checking the Chart - The USA Commerce (NYSE:BMY) - February 17 at 6:11 PM


What is Bristol-Myers Squibb Company's stock symbol?

Bristol-Myers Squibb Company trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

How often does Bristol-Myers Squibb Company pay dividends? What is the dividend yield for Bristol-Myers Squibb Company?

Bristol-Myers Squibb Company announced a quarterly dividend on Thursday, December 8th. Investors of record on Friday, January 6th will be given a dividend of $0.39 per share on Wednesday, February 1st. This represents a $1.56 annualized dividend and a yield of 2.80%. The ex-dividend date is Wednesday, January 4th. This is a boost from Bristol-Myers Squibb Company's previous quarterly dividend of $0.38.

Where is Bristol-Myers Squibb Company's stock going? Where will Bristol-Myers Squibb Company's stock price be in 2017?

20 brokers have issued 12-month target prices for Bristol-Myers Squibb Company's shares. Their predictions range from $42.00 to $75.00. On average, they expect Bristol-Myers Squibb Company's share price to reach $61.83 in the next year.

When will Bristol-Myers Squibb Company announce their earnings?

Bristol-Myers Squibb Company is scheduled to release their next quarterly earnings announcement on Wednesday, April, 26th 2017.

What are analysts saying about Bristol-Myers Squibb Company stock?

Here are some recent quotes from research analysts about Bristol-Myers Squibb Company stock:

  • Jefferies Group LLC analysts commented, "Management seems to have scared investors out of the stock by saying they were "committed to" rather than confident on the Opdivo/ Yervoy combo. We see the guidance cut as a casualty of the new era of conservatism at BMY, though the market seems convinced MRK will get KN-021(G) approved by May anyway. We see a potential acquisition of BMY as increasingly likely as the stock moves towards our ex-lung valuation of $44." (1/27/2017)
  • According to Zacks Investment Research, "Bristol-Myers key products – Opdivo, Orencia, Eliquis and Sprycel – should continue to fuel top-line growth of the company. The company raised its 2016 earnings guidance buoyed by strong trends across the business and posted an encouraging 2017 earnings outlook. Meanwhile, Bristol-Myers’ efforts to develop its pipeline are impressive. However, shares are under pressure with investors expressing disappointment over the company’s failed efforts to expand its key product Opdivo’s label to include the first-line treatment of lung cancer, which could give an edge to its competitors. The company announced that it will not seek an accelerated approval in the U.S. for Opdivo plus Yervoy, for first-line lung cancer. Shares of the company have underperformed that of the industry in the last one year. Moreover, estimates have come down ahead of the fourth-quarter results." (1/24/2017)

  • BMO Capital Markets analysts commented, "Our recent survey with 31 oncologists across the U.S. supports our cautious views on BMY's IO franchise. 4Q16 should be O.K. as the IO franchise will likely beat because the Street is missing ex-US deferred revenue, but the focus remains on longer term outlook. 2017 EPS guidance could be lowered to account for NSCLC competitive dynamics and 3-5% Fx headwind. With ongoing setbacks in IO, we see increased execution risk. Given increased uncertainty about the potential of the IO franchise, we think a takeout/merger is less likely. We remain cautious." (1/23/2017)
  • SunTrust Banks, Inc. analysts commented, "Our '17E EPS decreases to $3.02 (from $3.29) vs. Street's $3.00. We lowered our PT to $62 (from $68) & maintained our Hold rating. Our $62PT is based on 20x our '17E EPS. BMY needs positive expressers arm of CM-227 to stop in 2017 for it to execute on its IO-IO combo strategy."On October 9, Bristol-Myer disclosed in a statement, "Two pivotal Phase 3 studies, CheckMate -057 and CheckMate -017, which showed more than one-third of previously treated metastatic non-small cell lung cancer (NSCLC) patients in both trials experienced ongoing responses with Opdivo, compared to no ongoing responses in the docetaxel arm." (10/10/2016)

Who owns Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock is owned by many different of institutional and retail investors. Top institutional investors include State Street Corp (4.05%), FMR LLC (2.71%), Janus Capital Management LLC (1.19%), Loomis Sayles & Co. L P (0.82%), Bessemer Group Inc. (0.20%) and New York State Teachers Retirement System (0.18%). Company insiders that own Bristol-Myers Squibb Company stock include Autenried Paul Von, Charles A Bancroft, Francis M Cuss, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler and Sandra Leung.

Who sold Bristol-Myers Squibb Company stock? Who is selling Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Janus Capital Management LLC, Fred Alger Management Inc., FMR LLC, RidgeWorth Capital Management LLC, Orbimed Advisors LLC, FIL Ltd and William Blair Investment Management LLC. Company insiders that have sold Bristol-Myers Squibb Company stock in the last year include Autenried Paul Von, Charles A Bancroft, Giovanni Caforio, John E Elicker, Joseph C Caldarella, Lamberto Andreotti, Lewis B Campbell, Louis S Schmukler and Sandra Leung.

Who bought Bristol-Myers Squibb Company stock? Who is buying Bristol-Myers Squibb Company stock?

Bristol-Myers Squibb Company's stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Asset Management One Co. Ltd., Bessemer Group Inc., AMF Pensionsforsakring AB, Congress Asset Management Co. MA, Appaloosa LP, RTW Investments LP and Ardevora Asset Management LLP.

How do I buy Bristol-Myers Squibb Company stock?

Shares of Bristol-Myers Squibb Company can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bristol-Myers Squibb Company stock cost?

One share of Bristol-Myers Squibb Company stock can currently be purchased for approximately $55.77.

Bristol-Myers Squibb Company (NYSE:BMY) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Earnings History Chart

Earnings by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Dividend History Chart

Dividend Payments by Quarter for Bristol-Myers Squibb Company (NYSE:BMY)

Last Updated on 2/24/2017 by Staff